Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Tox trouble stalls Sosei/Allergan Alzheimers drug

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Tox trouble stalls Sosei/Allergan Alzheimer’ s drug. Surprise findings from primate studies. ... of muscarinic agonists for the treatment of major neurological disorders, including Alzheimer’s disease.

Latest news

More from news
Approximately 100 fully matching, plus 418 partially matching documents found.

Latest Intelligence

  • What can pharma learn from the charity sector? What can pharma learn from the charity sector?

    the charity sector (or third sector, as it’s also known) to better support its patients. ... Dr Doug Brown, Chief Policy and Research Officer at Alzheimer’s Society, explains how co-creation is an essential part of its research process:.

  • Deal Watch January 2018

    leukaemia (ALL), Juno's share price had been in the low $20s for several months. ... Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at

  • The good, the bad and the ugly The good, the bad and the ugly

    Alzheimer’s - where 98% of drugs fail Phase III trials. ... This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    Our work gives tremendous hope for Parkinson’s and also other cognitive conditions such as Alzheimer’s, if we can broaden the technology in the future.”. ... Since this article was written Pfizer has substantially scaled back its neuroscience R&D

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    Technology’s role in precision medicine is impacting the way researchers and clinicians are able to explain and predict health-related outcomes. ... burden and mild cognitive impairment in potential candidates for an Alzheimer’s study.

More from intelligence
Approximately 1 fully matching, plus 36 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Alzheimers disease: reviewing the immediate treatment horizon

    Alzheimer’ s disease: reviewing the immediate treatment horizon. Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to ... A recent article by BLH Consultant David Cooney

  • Alzheimer's: the numbers we cannot forget

    I would love to be talking about our latest thinking around launching new therapies in Alzheimer’ s disease (AD) but I can’ t – no one can. ... Among the worst attrition rates in the industry. 99.6% of all trials in Alzheimer’ s disease (AD)

  • Forecasting in Forgotten Markets

    This charitable fund represents collaboration between the Department of Health, Alzheimer’ s Research UK () and a number of Big Pharma companies. ... It’ s early days for this approach but there does appear to be some advantages.

  • Alzheimer's and Brain Awareness Month

    June 2017 is Alzheimer’ s and Brain Awareness Month, which aims to raise awareness about Alzheimer’ s disease (AD) and other types of dementia1. ... 5. Alzheimer's hopes dashed as Lilly gives up on amyloid drug solanezumab.

  • Atlantis Healthcare

    These include a patient’s environment, condition and motivation – along with other key behavioural drivers. ... We have delivered over 130 international support programmes across 90+ disease states including, among others: Alzheimer’s disease.

More from PMHub
Approximately 4 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics